Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1099.62
ACHN's Cash to Debt is ranked higher than
57% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. ACHN: 1099.62 )
Ranked among companies with meaningful Cash to Debt only.
ACHN' s Cash to Debt Range Over the Past 10 Years
Min: 1.1  Med: 144.77 Max: No Debt
Current: 1099.62
Equity to Asset 0.97
ACHN's Equity to Asset is ranked higher than
97% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ACHN: 0.97 )
Ranked among companies with meaningful Equity to Asset only.
ACHN' s Equity to Asset Range Over the Past 10 Years
Min: -6.98  Med: 0.66 Max: 0.97
Current: 0.97
-6.98
0.97
F-Score: 6
Z-Score: 47.72
M-Score: 495.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -21.82
ACHN's Operating margin (%) is ranked higher than
62% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. ACHN: -21.82 )
Ranked among companies with meaningful Operating margin (%) only.
ACHN' s Operating margin (%) Range Over the Past 10 Years
Min: -17954.25  Med: -747.67 Max: 11935.9
Current: -21.82
-17954.25
11935.9
Net-margin (%) -5.78
ACHN's Net-margin (%) is ranked higher than
67% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. ACHN: -5.78 )
Ranked among companies with meaningful Net-margin (%) only.
ACHN' s Net-margin (%) Range Over the Past 10 Years
Min: -17897.17  Med: -713.80 Max: 12030.34
Current: -5.78
-17897.17
12030.34
ROE (%) -1.05
ACHN's ROE (%) is ranked higher than
74% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. ACHN: -1.05 )
Ranked among companies with meaningful ROE (%) only.
ACHN' s ROE (%) Range Over the Past 10 Years
Min: -199.15  Med: -72.76 Max: -1.7
Current: -1.05
-199.15
-1.7
ROA (%) -0.99
ACHN's ROA (%) is ranked higher than
75% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. ACHN: -0.99 )
Ranked among companies with meaningful ROA (%) only.
ACHN' s ROA (%) Range Over the Past 10 Years
Min: -103.25  Med: -58.49 Max: -1.62
Current: -0.99
-103.25
-1.62
ROC (Joel Greenblatt) (%) -196.53
ACHN's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. ACHN: -196.53 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ACHN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -6066.62  Med: -2847.52 Max: -287.49
Current: -196.53
-6066.62
-287.49
Revenue Growth (3Y)(%) 146.80
ACHN's Revenue Growth (3Y)(%) is ranked higher than
97% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. ACHN: 146.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ACHN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -100.00 Max: 146.8
Current: 146.8
0
146.8
EBITDA Growth (3Y)(%) -62.20
ACHN's EBITDA Growth (3Y)(%) is ranked lower than
96% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. ACHN: -62.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ACHN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -50.10 Max: 4.3
Current: -62.2
0
4.3
EPS Growth (3Y)(%) -60.30
ACHN's EPS Growth (3Y)(%) is ranked lower than
95% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. ACHN: -60.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ACHN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -65.5  Med: -32.10 Max: 3.5
Current: -60.3
-65.5
3.5
» ACHN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ACHN Guru Trades in Q2 2015

Steven Cohen 8,388,200 sh (New)
Paul Tudor Jones 10,400 sh (New)
» More
Q3 2015

ACHN Guru Trades in Q3 2015

Steven Cohen 9,772,018 sh (+16.50%)
Paul Tudor Jones Sold Out
» More
Q4 2015

ACHN Guru Trades in Q4 2015

Jim Simons 111,400 sh (New)
Steven Cohen 8,966,608 sh (-8.24%)
» More
Q1 2016

ACHN Guru Trades in Q1 2016

Joel Greenblatt 554,125 sh (New)
Paul Tudor Jones 39,959 sh (New)
Steven Cohen 9,103,921 sh (+1.53%)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ACHN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:FPRX, OTCPK:MPSYY, NAS:CXRX, NAS:HALO, NAS:AAAP, NAS:MCRB, NAS:TBPH, OTCPK:SXMDF, OTCPK:BVNRY, NAS:ACOR, NYSE:AXON, NAS:INVA, NYSE:EBS, NYSE:PBYI, OTCPK:GENSF, NAS:PRTA, NAS:ALDR, NAS:ONCE, NAS:FGEN, NAS:XLRN » details
Traded in other countries:ADA.Germany,
Achillion Pharmaceuticals Inc is a biopharmaceutical company which focuses on the discovery, development and commercialization of treatments for infectious diseases like hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free.

Achillion Pharmaceuticals Inc was incorporated on August 17, 1998 in Delaware. The Company is a biopharmaceutical company which focuses on the discoveries, develops and commercializes treatments for infectious diseases. Within the anti-infective market, it is currently focusing its efforts on developing commercially competitive, short-duration combination therapies for the treatment of chronic hepatitis C infection that are administered once-daily, orally, and without ribavirin. The Company competes with Abbvie, Astra-Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Enanta, Gilead, GlaxoSmithKline, Idenix, Johnson & Johnson, Presidio, Medivir, Merck, Novartis, Pfizer, Roche, Valeant and Vertex. The Company's drug candidates is subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, record keeping, labeling, marketing and distribution of drugs.

Ratios

vs
industry
vs
history
P/B 2.42
ACHN's P/B is ranked higher than
61% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. ACHN: 2.42 )
Ranked among companies with meaningful P/B only.
ACHN' s P/B Range Over the Past 10 Years
Min: 0.79  Med: 3.75 Max: 12.16
Current: 2.42
0.79
12.16
P/S 15.60
ACHN's P/S is ranked lower than
61% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. ACHN: 15.60 )
Ranked among companies with meaningful P/S only.
ACHN' s P/S Range Over the Past 10 Years
Min: 0.84  Med: 253.43 Max: 7995
Current: 15.6
0.84
7995
PFCF 3900.00
ACHN's PFCF is ranked lower than
99% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 26.54 vs. ACHN: 3900.00 )
Ranked among companies with meaningful PFCF only.
ACHN' s PFCF Range Over the Past 10 Years
Min: 3630  Med: 4070.00 Max: 4820
Current: 3900
3630
4820
POCF 780.00
ACHN's POCF is ranked lower than
99% of the 183 Companies
in the Global Biotechnology industry.

( Industry Median: 22.98 vs. ACHN: 780.00 )
Ranked among companies with meaningful POCF only.
ACHN' s POCF Range Over the Past 10 Years
Min: 726  Med: 814.00 Max: 964
Current: 780
726
964
Current Ratio 32.91
ACHN's Current Ratio is ranked higher than
97% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ACHN: 32.91 )
Ranked among companies with meaningful Current Ratio only.
ACHN' s Current Ratio Range Over the Past 10 Years
Min: 1.06  Med: 6.42 Max: 32.91
Current: 32.91
1.06
32.91
Quick Ratio 32.91
ACHN's Quick Ratio is ranked higher than
97% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. ACHN: 32.91 )
Ranked among companies with meaningful Quick Ratio only.
ACHN' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 6.42 Max: 32.91
Current: 32.91
1.06
32.91
Days Sales Outstanding 5.06
ACHN's Days Sales Outstanding is ranked higher than
92% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. ACHN: 5.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACHN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.29  Med: 62.56 Max: 152.21
Current: 5.06
12.29
152.21

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.50
ACHN's Price/Net Cash is ranked higher than
77% of the 504 Companies
in the Global Biotechnology industry.

( Industry Median: 5.38 vs. ACHN: 2.50 )
Ranked among companies with meaningful Price/Net Cash only.
ACHN' s Price/Net Cash Range Over the Past 10 Years
Min: 0.82  Med: 5.19 Max: 12.7
Current: 2.5
0.82
12.7
Price/Net Current Asset Value 2.48
ACHN's Price/Net Current Asset Value is ranked higher than
77% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 5.07 vs. ACHN: 2.48 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ACHN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.78  Med: 4.88 Max: 12.29
Current: 2.48
0.78
12.29
Price/Tangible Book 2.45
ACHN's Price/Tangible Book is ranked higher than
68% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 3.99 vs. ACHN: 2.45 )
Ranked among companies with meaningful Price/Tangible Book only.
ACHN' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.72  Med: 4.33 Max: 81.84
Current: 2.45
0.72
81.84
Price/Median PS Value 0.06
ACHN's Price/Median PS Value is ranked higher than
98% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. ACHN: 0.06 )
Ranked among companies with meaningful Price/Median PS Value only.
ACHN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 0.63 Max: 17.16
Current: 0.06
0.01
17.16
Earnings Yield (Greenblatt) (%) -0.63
ACHN's Earnings Yield (Greenblatt) (%) is ranked higher than
70% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. ACHN: -0.63 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ACHN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -0.69  Med: 361.00 Max: 15068.8
Current: -0.63
-0.69
15068.8

More Statistics

Revenue (TTM) (Mil) $66.12
EPS (TTM) $ -0.07
Beta1.97
Short Percentage of Float13.37%
52-Week Range $5.57 - 10.95
Shares Outstanding (Mil)136.64

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 75 260
EPS ($) -0.58 0.04 1.60
EPS w/o NRI ($) -0.58 0.04 1.60
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for ACHN

Headlines

Articles On GuruFocus.com
UBS and JMP Securities Downgrade Achillion Pharmaceuticals Inc.(ACHN) Following Johnson & Johnson (J May 21 2015 
Dycom Industries (DY) Surpasses Estimates; Achillion Pharma (ACHN) Inks Mega-Deal with Janssen May 20 2015 
Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 
Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
Top 4 Insider Buys of Last Week Jun 10 2013 
Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster Beverage Corp, CarMax Inc, and Im Jan 23 2012 
Weekly CEO Sells Highlight: UNH, LRY, ACHN, RPM Jan 16 2012 
Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Oct 27 2010 

More From Other Websites
Achillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : June 21, 2016 Jun 21 2016
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US :... Jun 20 2016
Achillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D... Jun 10 2016
Achillion to Present at Three Upcoming Investor Conferences Jun 01 2016
Achillion to Present at Three Upcoming Investor Conferences Jun 01 2016
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... May 27 2016
What Hedge Funds Think About Achillion Pharmaceuticals, Inc. (ACHN)? May 23 2016
Achillion Announces Acceptance of Late Breaking Abstract for ACH-4471 at the 21st Congress of the... May 19 2016
ETF’s with exposure to Achillion Pharmaceuticals, Inc. : May 11, 2016 May 11 2016
ACHILLION PHARMACEUTICALS INC Financials May 10 2016
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US :... May 10 2016
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 03 2016
ACHILLION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 03 2016
Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs May 03 2016
Achillion reports 1Q loss May 03 2016
Achillion reports 1Q loss May 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)